Green, John

JohnGreen.jpg

Job Title: Consultant in Medical Oncology

Qualifications: BSc, MBChB, FRCP, MD

Speciality: Medical Oncology

GMC Number: 1337747

Membership/Appointments:
Member, EORTC Gynaecological Cancer Group - 1993 to present
Regional Specialty Adviser, Royal College of Physicians – 2000-2016
Programme Coordinator, MSc Medical Sciences (Oncology), University of Liverpool – 1993-1999
Clinical advisor, Online CPD programme “Acute Cancer Medicine” – 2011 to present
Council Member, European Society for Gynaecological Cancer – 2011 to 2015
Steering Group Member, European Ovarian Cancer Translational Network (EUTROC)- 2010 to present
Editorial Board Member of the International Journal of Gynaecological Cancer – 2011 to present

Clinics: Liverpool Women’s

Tumour site(s): Gynaecology

Details:

I am an experienced medical oncologist who has held a number of senior executive and non-executive roles at an international level in oncology and particularly in translational research. My current clincial interests are exclusively in gynaecological cancer, although I retain an interest in biomarker studies in relation to targeted thereapies for lung cancer. My career spans the development of molecular genetics and molecular oncology, and I have progressed from first hand experience of laboratory research at undergraduate and postgraduate (NCI Bethesda) level, research management and secondary research evaluating systematic synthesis of phase three data. The majority of my recent work has been in ovarian cancer, looking at drug resistance. This has also involved studies of the BRCA genes and DNA repair which link breast and ovarian cancers in both biology and therapy, as the PARP inhibitor has recently been approved by NICE in BRCA germline positive patients . My recent role as CI on the novel compound APR 246 in high grade serous ovarian cancer, targeting the mutant p53 gene, has made use of expertise in histopathology, clinical trial work, biomarker evaluation and wide knowledge of cancer therapy. Before that, I played a major part in the development of filgrastim by Roche and Amgen which reduces the risk of neutropenic chemotherapy, which was instrumental in improving the mortality and morbidity of the majority of anticancer compounds, as well as giving me first hand experience of the introduction of novel agents into clinical practice.

From 2011-2015 I was elected as a Council member for ESGO, a European based professional society which promoted itself as the voice of gynaecological oncology in Europe. This followed a period as secretary of the British Society of Gynaecological Oncology. The major influence of the Society is in pelvic cancers, although 10% of the activity is in relation to breast cancer. I was given responsibility for the development of patient networks, an educational and advocacy role which extended to all aspects of these cancers, and became closely linked with the BRCA positive patient lobby. A second role was in relation to INTEGRATE, an umbrella organisation supported by ESGO to promote translational research in ovarian, endometrial and cervical cancer in Europe. I am on the organising committee of the State of the Art meeting on gynaecological cancer ( including breast) prevention in Antalya in September 2016.

In 2010 I was one of a small group who set up EUTROC, initially an academic network which grew to include key pharmaceutical company representatives and currently has two innovative phase 2 trials, one a trial in HGSOC looking at reversal of p53 unfolding with the SME Aprea and the second with Takeda looking at dual TORC inhibition in ovarian and endometrial cancer. These trials have integral translational studies and are carried out in selected gynaecological cancer centres in Europe, but with buy-in from US centres. In respect of APR 246 I have been the chief investigator for the Phase 1b/ll. The phase 1b has just been completed with a maximal tolerated dose established, and led to presentations at AACR, ASCO and TAT. I have been working with the company to advise on further development and was recently part of the team seeking advice from the EMA.

I have held my current position with the University of Liverpool for several years although the job has evolved considerably over that time. My clinical practice in lung, melanoma and sarcoma has progressively given way to a focus on gynaecological cancer in my 6 clinical sessions divided between The Clatterbridge Cancer Centre and the Liverpool Women's hospital, which together serve a population of 2 million in the north of England. My University time (5 sessions) is spent conducting clinical trials and working with two small research groups in Liverpool, co-supervising 2 PhD students investigating stem cells in endometrial cancers and invasion and metastasis genes in ovarian cancer models. I have also developed online M level learning programmes for medical and specialist nursing staff, incorporating state of the art technology (including vídeo) and pedagogy.

My administrative experience includes chairing meetings at a high level. I recently stepped down from membership of ESGO Council (www.esgo.org) where I organised international meetings, spoke at many workshops and conferences across Europe and set up and chaired the patient network ENGAGe. Formerly I was active in the EORTC and NCRI Gynaecological Cancer Groups, set up and chaired their Translational Research subcommittees and also represented both organisations on the Gynaecological Cancer Intergroup, an international consortium of trial groups. One development I would like to encourage is greater dialogue between clinical research organisations across tumour site boundaries.